The research interests of KMarie Reid Lombardo, M.D., M.S., focus on how host susceptibility, environmental factors — namely, smoking — and nonsteroidal anti-inflammatory drugs facilitate the association between inflammation and pancreatic adenocarcinoma via genetic polymorphisms of inflammation-related genes. In addition, Dr. Reid Lombardo examines how the presence of polymorphisms in pancreatic cancer patients affects their survival after surgical resection.
The overall goal of Dr. Reid Lombardo's research is to identify a cause of pancreatic cancer in which a biomarker for risk or target for chemoprevention can be elucidated in order to decrease the impact of this very lethal disease.
- Outcome prediction. Dr. Reid Lombardo is working to identify genetic markers that can predict outcomes after surgery for pancreatic cancer.
- Risk identification. An additional area of focus is identification of a biomarker for risk of pancreatic cancer to impact the outcome of this morbid disease.
Significance to patient care
Pancreatic cancer, a lethal malignancy, afflicts over 33,000 people annually in the United States. Though much investigation is underway to clarify the biology and natural history of this disease, even basic questions, such as the cause of the disease, remain unknown. There is, however, more than suggestive evidence in the literature of a link between chronic inflammation and progression to pancreatic cancer. Understanding this link can help to elucidate how to modify the morbid outcome of pancreas surgery by way of surgical and chemotherapeutic strategies.